Li Zhang

机构：Nanchang University, Sun Yat-sen University, Shanghai East Hospital, Sun Yat-sen University Cancer Center, Guangdong Provincial People's Hospital, Shanghai Municipal Center For Disease Control Prevention, State Key Laboratory of Oncology in South China · ORCID：0000-0002-7000-2955

发表论文 123 篇 · 总被引 15454 次 · h-index 31

代表论文

• Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer (2024 · Journal of Clinical Oncology · 被引 154)
• Brain Radiotherapy With Pyrotinib and Capecitabine in Patients With ERBB2 -Positive Advanced Breast Cancer and Brain Metastases (2024 · JAMA Oncology · 被引 30)
• Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer (2024 · ESMO Open · 被引 22)
• Overdiagnosis of Lung Cancer Due to the Introduction of Low-Dose Computed Tomography in Average-Risk Populations in the People’s Republic of China (2025 · Journal of Thoracic Oncology · 被引 20)
• Dual Inhibition of CDK4/6 and CDK7 Suppresses Triple‐Negative Breast Cancer Progression via Epigenetic Modulation of SREBP1‐Regulated Cholesterol Metabolism (2024 · Advanced Science · 被引 13)
• Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study. (2025 · Journal of Clinical Oncology · 被引 10)